PDS Biotechnology Corporation has appointed John Dawson CBE, Deborah Ramsdell, and Bruce Wendel to its Board of Directors, bringing extensive experience in drug development, commercialization, and regulatory affairs. These appointments coincide with the company’s progress toward a Phase 3 trial for its metastatic colorectal cancer drug candidate PDS0301 and partnership efforts for PDS0101. The new board members are expected to support PDS Biotech’s strategic growth and clinical development plans as it advances its immunotherapy pipeline.
The story about PDS Biotechnology appointing new board members comes as the Health sector on Pluang shows mixed activity. For readers following Health-sector stocks, here is Pluang's market snapshot as of Oct 20, 2026 19:03 WIB: out of 150 priced US Health stocks, 81 rose and 62 fell. Notable movers include RXRX at USD 3.54 with a 72% sell order activity, ALC at USD 67.41 with 100% buy order activity, and NUVB at USD 4.40 with a typical hold time of 11 days.
Hershey is preparing to announce its Q3 earnings on October 29, with analysts forecasting earnings per share (EPS) of $2.12, a 63% increase from last year, and revenue of $3.25 billion, up 2.3%. The company has shown strong recent performance, with Q...
3M reported strong Q3 2026 earnings with adjusted EPS of $2.50, beating estimates of $2.38, and GAAP profit rising to $1.37 billion from $834 million a year earlier. Sales reached $6.6 billion, slightly below estimates, but showed 3.3% organic growth...
Alaska Air Group is set to report Q3 2026 earnings with analysts expecting a 66.7% drop in earnings per share to $0.35, despite a 14.5% increase in revenue to $4.31 billion driven by strong travel demand. Passenger revenue is forecast to rise 10.2%, ...
Baba, an applied AI company focused on modernizing Medicare and Medicaid care, has raised $40 million in a Series A funding round led by FirstMark Capital, with participation from CVS Health Ventures and others. The funding will help Baba expand its ...
Richard Campbell-Breeden, a seasoned investment banker with 37 years of experience including 27 years at Goldman Sachs, has joined SEDA Experts LLC as Managing Director. His expertise in mergers and acquisitions, corporate finance, and governance wil...
